|
|
7811 Eads Ave. Suite 112
La Jolla, CA 92037
phone:858-551-0096
fax: |
| Symbol |
Private |
| Founded |
2006 |
| Employees |
|
|
|
| freedom-meditech.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Non-Invasive Ocular Glucose Measurement |
|
| Management |
| Craig H. Misrach, M.B.A., C.P.A., President and Chief Executive Officer; Brent D. Cameron, Ph.D., Chief Scientific Officer; Brian Catanzaro, Ph.D., VP of Product Development, Lead Optical Engineer
|
|
|
| |
| Keywords |
| Patient Monitoring, Diabetes, Ophthalmology, Glucose Measurement, Ocular Polarimetry |
|
|
|
|
|
| Description |
|
Freedom Meditech, Inc. is a developmental stage medical device company focused on the in-licensing, development, and commercialization of novel technologies for the management of diabetes. |
|
| Technology / Differentiation |
| Freedom Meditech's current core proprietary technology is a novel eye-related diabetes medical device that is being developed so to provide diabetic persons with a more convenient and pain-free alternative to the 'finger prick' method of glucose measurement and monitoring. Our patented technology platform 1) is non-invasive, 2) entails shining a light in a person's eye to obtain glucose information, and 3) is being designed to display glucose information in digital format on the handheld device (the size of small binoculars) taking the reading. |
|
| Market / Customers |
The worldwide diabetes market is currently estimated at $8 billion; the company's product presents significant potential in this market since no non-invasive blood glucose measuring device has yet been approved by the FDA.
|
|
| Strategy |
The company was incorporated in December 2006, with activities to-date including; due diligence on numerous early-stage medical device technologies, related research, intellectual property (IP) evaluation, management/advisor recruiting, product development planning, licensing negotiations, and business development activities. Freedom Meditech has been founded with the intent of licensing, developing, and commercializing medical device technologies with clear market need and overall global appeal.
|
|
| Status |
| he company anticipates $2.5 million in Series A Preferred Equity Financing and is currently raising capital for pilot human studies. |
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
